摘要
经皮冠状动脉介入治疗(percutaneous coronary intervention,PCI)围术期抗血小板治疗可明显降低PCI术后心血管事件及病死率。近年大量循证医学证据不断涌现,新的抗血小板药物不断研制开发,但临床如何权衡支架内血栓形成及出血的风险,制定个体化的治疗方案,对降低PCI围术期心脏事件至关重要。本文复习近年相关资料,为临床PCI围术期规范化使用抗血小板药物提供借鉴。
Perioperative anti platelet therapy can significantly reduce cardiovascular events and mortality of patients after percutaneous coronary intervention（PCI）. With growing evidences of evidence based medicine and development of new anti- platelet agents in recent years, it is of vital importance to balance risks of thrombosis and hemorrhage, to develop personalized treatment regimen and to reduce cardiovascular events during PCI perioperation. This paper is a review of recent progress in anti-platelet therapy in PCI, which could provide evidence for standard medication of anti platelet agents in PCI perioperation.
出处
《药学服务与研究》
CAS
CSCD
2014年第4期241-244,共4页
Pharmaceutical Care and Research
基金
国家科技重大专项重大新药创制资助项目(2011ZX09302-002-02)
